Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epofolate in advanced cancer
NCT00550017Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2007
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of epofolate in solid tumor (advanced stage), ovarian cancer, renal cell carcinoma (RCC) and 1 more, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Tolerated Dose, Dose Limiting Toxicity and 1 more. Started Dec 2007; status: terminated.
02
Drugs
epofolate
03
Conditions
solid tumor (advanced stage)ovarian cancerrenal cell carcinoma (RCC)breast cancer
Beyond the preview
Go deeper on NCT00550017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00550017.